Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) - Final appraisal document

In DRAFT guidance, NICE recommends ravulizumab as an option for treating aHUS in people weighing ≥10kg who have not had a complement inhibitor before or whose disease has responded to at least 3 months of eculizumab, if it is provided according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence